Stockreport

Motif Bio Announces Positive Topline Results for iclaprim in the REVIVE-2 Phase 3 Study

MOTIF BIO PLC ADRS  (MTFB) 
US:NASDAQ Investor Relations: ir.motifbio.com
PDF Iclaprim met the primary endpoint Iclaprim was well tolerated in the study NDA submission expected in the first quarter of 2018 Company to host a conference call today [Read more]